Mounjaro was developed by Eli Lilly and Company [1].
What is Mounjaro used for?
Mounjaro is a medication approved for the treatment of type 2 diabetes [2]. It is also being studied for its potential in weight management [3].
How does Mounjaro work?
Mounjaro contains tirzepatide, which acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [4]. This dual action helps to improve blood sugar control by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and reducing appetite [5].
When did Mounjaro get approved?
The U.S. Food and Drug Administration (FDA) approved Mounjaro for the treatment of type 2 diabetes in May 2022 [2].
What are the potential side effects of Mounjaro?
Common side effects reported for Mounjaro include nausea, vomiting, diarrhea, decreased appetite, and abdominal pain [6]. More serious side effects can include pancreatitis, gallbladder problems, kidney problems, and certain types of thyroid tumors [7]. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Mounjaro [7].
Are there alternatives to Mounjaro?
For type 2 diabetes management, other medications exist, including other GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide's predecessor, dulaglutide (Trulicity) [8]. For weight management, semaglutide (Wegovy) is also an option [3].
What is the patent status of Mounjaro?
Information regarding the specific patents protecting Mounjaro and its active ingredient, tirzepatide, can be found through resources like DrugPatentWatch.com [9]. Patents for drugs typically last for 20 years from the filing date, but extensions and other forms of intellectual property protection can influence the actual market exclusivity period [9].